Claims
- 1. ##STR11## wherein R.sub.1 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, thioalkoxy; and
- R.sub.2 is lower alkoxy;
- R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, halo, and thioalkoxy; or
- R.sub.1 and R.sub.2 taken together can form a methylenedioxy or ethylenedioxy bridge; and
- R.sub.7 is phenyl, thienyl, furyl or substituted phenyl wherein the phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, and thioalkoxy; or
- a pharmaceutically acceptable salt thereof.
- 2. 5,6-Methylenedioxy-1-(3-phenylpyrrolidino-1-methyl) tetralin or a pharmaceutically acceptable salt thereof.
- 3. A compound selected from:
- 5,6-Methylenedioxy-1R*-(3R*-phenylpyrrolidino-1-methyl) tetralin or a pharmaceutically acceptable salt thereof; and
- 5,6-Methylenedioxy-1S*-(3*-phenylpyrrolidino-1-methyl)-tetralin or a pharmaceutically acceptable salt thereof; or a mixture of the two.
- 4. A compound selected from
- 5,6-Methylenedioxy-1R*-(3S*-phenylpyrrolidino-1-methyl) tetralin or a pharmaceutically acceptable salt thereof; and
- 5,6-Methylenedioxy-1S*-(3R*-phenylpyrrolidino-1-methyl)-tetralin or a pharmaceutically acceptable salt thereof; or a mixture of the two.
- 5. 8-Fluoro-5,6-methylenedioxy-1-(3-phenylpyrrolidino-1-methyl) tetralin or a pharmaceutically acceptable salt thereof.
- 6. 5,6-Methylenedioxy-1-(3R-(o-fluorophenyl)-pyrrolidion-1R-methyl) tetralin or a pharmaceutically acceptable salt thereof.
- 7. 5,6-Methylenedioxy-1-(3S-(o-fluorophenyl)-pyrrolidion-1R-methyl) tetralin or a pharmaceutically acceptable salt thereof.
- 8. A compound as defined by claim 1 wherein R.sub.1 and R.sub.2 together are methylenedioxy or ethylenedioxy; or a pharmaceutically acceptable salt thereof.
- 9. A compound as defined by claim 1 wherein R.sub.7 is phenyl or substituted phenyl wherein the phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, and thioalkoxy; or a pharmaceutically acceptable salt thereof.
- 10. A pharmaceutical composition for selectively inhibiting .alpha..sub.2 adrenergic receptors comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula: ##STR12## wherein R.sub.1 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, thioalkoxy; and
- R.sub.2 is lower alkoxy;
- R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, halo, and thioalkoxy; or
- R.sub.1 and R.sub.2 taken together can form a methylenedioxy or ethylenedioxy bridge; and
- R.sub.7 is phenyl, thienyl, furyl or substituted phenyl whereinthe phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, and thioalkoxy; or
- a pharmaceutically acceptable salt thereof.
- 11. A pharmaceutical composition for treating depression comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula: ##STR13## wherein R.sub.1 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, thioalkoxy; and
- R.sub.2 is lower alkoxy;
- R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, halo, and thioalkoxy; or
- R.sub.1 and R.sub.2 taken together can form a methylenedioxy or ethylenedioxy bridge; and
- R.sub.7 is phenyl, thienyl, furyl or substituted phenyl wherein the phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, and thioalkoxy; or
- a pharmaceutically acceptable salt thereof.
- 12. The composition of claim 11 wherein the compound is selected from:
- 5,6-Methylenedioxy-1R*-(3R*-phenylpyrrolidino-1-methyl) tetralin or a pharmaceutically acceptable salt thereof; and
- 5,6-Methylenedioxy-1S*-(3S*-phenylpyrrolidino-1-methyl)-tetralin or a pharmaceutically acceptable salt thereof; or a mixture of the two.
- 13. A pharmaceutical composition for inhibiting biogenic amine uptake comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula: ##STR14## wherein R.sub.1 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, thioalkoxy; and
- R.sub.2 is lower alkoxy;
- R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, halo, and thioalkoxy; or
- R.sub.1 and R.sub.2 taken together can form a methylenedioxy or ethylenedioxy bridge; and
- R.sub.7 is phenyl, thienyl, furyl or substituted phenyl wherein the phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, and thioalkoxy; or
- a pharmaceutically acceptable salt thereof.
- 14. A method for selectively inhibiting alpha-2-adrenergic receptors comprising administering to a patient in need a therapeutically effective amount of a compound of the formula: ##STR15## wherein R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halo, and thioalkoxy; and
- R.sub.2 is lower alkoxy;
- R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, halo, and
- thioalkoxy; or
- R.sub.1 and R.sub.2 taken together can form a methylenedioxy or ethylenedioxy bridge; and
- R.sub.7 is phenyl, thienyl, furyl or substituted phenyl wherein the phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from loweralkyl, halo, hydroxy, lower alkoxy, amino and thioalkoxy; or
- a pharmaceutically acceptable salt thereof.
- 15. A method of treating depression comprising administering to a patient in need, a therapeutically effective amount of a compound of the formula: ##STR16## wherein R.sub.1 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, thioalkoxy; and
- R.sub.2 is lower alkoxy;
- R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, halo, and thioalkoxy; or
- R.sub.1 and R.sub.2 taken together can form a methylenedioxy or ethylenedioxy bridge; and
- R.sub.7 is phenyl, thienyl, furyl or substituted phenyl wherein the phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, and thioalkoxy; or
- a pharmaceutically acceptable salt thereof.
- 16. A method for inhibiting biogenic amine uptake comprising administering to a patient in need a therapeutically effective amount of a compound of the formula: ##STR17## wherein R.sub.1 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, thioalkoxy; and
- R.sub.2 is lower alkoxy;
- R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, halo, and thioalkoxy; or
- R.sub.1 and R.sub.2 taken together can form a methylenedioxy or ethylenedioxy bridge; and
- R.sub.7 is phenyl, thienyl, furyl or substituted phenyl wherein the phenyl ring is substituted with methylenedioxy, ethylenedioxy or with one or two substituents independently selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, and thioalkoxy; or
- a pharmaceutically acceptable salt thereof.
Parent Case Info
This is a continuation-in part of U.S. Pat. application Ser. No. 07/555501 as PCT/US89/00140, filed Jan. 13, 1989, which is a continuation in part of U.S. Pat. application Ser. No. 144,364, filed Jan. 15, 1988 (now abandoned).
US Referenced Citations (4)
Foreign Referenced Citations (1)
Number |
Date |
Country |
2093837 |
Sep 1982 |
GBX |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
555501 |
Jan 1989 |
|
Parent |
144364 |
Jan 1988 |
|